Eric Meffre

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9252752/publications.pdf

Version: 2024-02-01

95 papers	12,550 citations	38742 50 h-index	49909 87 g-index
101 all docs	101 docs citations	101 times ranked	15340 citing authors

#	Article	IF	Citations
1	Positive and negative selection shape the human naive B cell repertoire. Journal of Clinical Investigation, 2022, 132, .	8.2	14
2	High-throughput identification of autoantibodies that target the human exoproteome. Cell Reports Methods, 2022, 2, 100172.	2.9	22
3	A Novel AICDA Splice-Site Mutation in Two Siblings with HIGM2 Permits Somatic Hypermutation but Abrogates Mutational Targeting. Journal of Clinical Immunology, 2022, 42, 771-782.	3.8	4
4	A humanized mouse model of chronic COVID-19. Nature Biotechnology, 2022, 40, 906-920.	17.5	71
5	Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature, 2022, 606, 585-593.	27.8	276
6	B-cell biology, tolerance, and autoantibodies. , 2021, , 71-80.		0
7	Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. Molecular Cell, 2021, 81, 2094-2111.e9.	9.7	17
8	Defective early B cell tolerance checkpoints in patients with systemic sclerosis allow the production of selfâ€antigenâ€specific clones. Arthritis and Rheumatology, 2021, , .	5.6	10
9	Pharmacological Targeting of PI3K-Dependent Central Tolerance Mechanisms in Refractory Pre-Germinal Center B-Cell Malignancies. Blood, 2021, 138, 2267-2267.	1.4	0
10	Autoreactivity in naÃ¯ve human fetal B cells is associated with commensal bacteria recognition. Science, 2020, 369, 320-325.	12.6	29
11	Interferon deficiency can lead to severe COVID. Nature, 2020, 587, 374-376.	27.8	73
12	Disease-associated CTNNBL1 mutation impairs somatic hypermutation by decreasing nuclear AID. Journal of Clinical Investigation, 2020, 130, 4411-4422.	8.2	11
13	Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses. Journal of Allergy and Clinical Immunology, 2019, 143, 258-265.	2.9	68
14	Human DEF6 deficiency underlies an immunodeficiency syndrome with systemic autoimmunity and aberrant CTLA-4 homeostasis. Nature Communications, 2019, 10, 3106.	12.8	48
15	A novel ATM mutation associated with elevated atypical lymphocyte populations, hyper-IgM, and cutaneous granulomas. Clinical Immunology, 2019, 200, 55-63.	3.2	8
16	B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. , 2019, 7, 153.		58
17	Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain, 2019, 142, 1598-1615.	7.6	62
18	Transitional B cells in quiescent SLE: An early checkpoint imprinted by IFN. Journal of Autoimmunity, 2019, 102, 150-158.	6.5	30

#	Article	IF	Citations
19	AIRE expression controls the peripheral selection of autoreactive B cells. Science Immunology, 2019, 4, .	11.9	65
20	Impaired Bâ€cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies. Immunological Reviews, 2019, 292, 90-101.	6.0	86
21	Impaired ATM activation in B cells is associated with bone resorption in rheumatoid arthritis. Science Translational Medicine, 2019, 11, .	12.4	15
22	Immunoepidemiology of Immune Dysfunction. , 2019, , 127-148.		0
23	Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling. Blood, 2019, 134, 393-393.	1.4	0
24	Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell Malignancies. Blood, 2019, 134, 295-295.	1.4	0
25	Accumulation of Antigen-Driven Lymphoproliferations in Complement Receptor 2/CD21â^'/low B Cells From Patients With SjÃ¶gren's Syndrome. Arthritis and Rheumatology, 2018, 70, 298-307.	5.6	24
26	The First B-Cell Tolerance Checkpoint in Mice and Humans: Control by AID. Advances in Immunology, 2018, 139, 51-92.	2.2	10
27	TACI Isoforms Regulate Ligand Binding and Receptor Function. Frontiers in Immunology, 2018, 9, 2125.	4.8	26
28	Reprogramming human T cell function and specificity with non-viral genome targeting. Nature, 2018, 559, 405-409.	27.8	630
29	Impaired TLR9 responses in B cells from patients with systemic lupus erythematosus. JCI Insight, 2018, 3, .	5.0	59
30	ZAP-70 Expression in Non Tumoral B Cells: Role in B Tolerance Breakdown?. Blood, 2018, 132, 1114-1114.	1.4	1
31	CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies. Blood, 2018, 132, 776-776.	1.4	0
32	A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production. Blood, 2017, 129, 959-969.	1.4	105
33	Self-reactive VH4-34â€"expressing IgG B cells recognize commensal bacteria. Journal of Experimental Medicine, 2017, 214, 1991-2003.	8.5	66
34	Germline hypomorphic CARD11 mutations in severe atopic disease. Nature Genetics, 2017, 49, 1192-1201.	21.4	174
35	Smith-Magenis Syndrome Patients Often Display Antibody Deficiency but Not Other Immune Pathologies. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1344-1350.e3.	3.8	11
36	Novel in vitro booster vaccination to rapidly generate antigen-specific human monoclonal antibodies. Journal of Experimental Medicine, 2017, 214, 2471-2490.	8.5	17

#	Article	IF	Citations
37	Brief Report: Defective Early B Cell Tolerance Checkpoints in SjÃ¶gren's Syndrome Patients. Arthritis and Rheumatology, 2017, 69, 2203-2208.	5.6	40
38	Peripheral VH4+Âplasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients. Acta Neuropathologica, 2017, 133, 43-60.	7.7	30
39	HSC extrinsic sex-related and intrinsic autoimmune diseaseâ€“related human B-cell variation is recapitulated in humanized mice. Blood Advances, 2017, 1, 2007-2018.	5.2	16
40	PTPN22 inhibition resets defective human central B cell tolerance. Science Immunology, 2016, 1, .	11.9	64
41	Big impact of microRNAs on central B cell tolerance. Nature Immunology, 2016, 17, 353-354.	14.5	0
42	CD19 controls Toll-like receptor 9 responses in human BÂcells. Journal of Allergy and Clinical Immunology, 2016, 137, 889-898.e6.	2.9	50
43	Maturational characteristics of HIV-specific antibodies in viremic individuals. JCI Insight, 2016, 1, .	5.0	42
44	Decreased somatic hypermutation induces an impaired peripheral B cell tolerance checkpoint. Journal of Clinical Investigation, 2016, 126, 4289-4302.	8.2	46
45	Deficiency of base excision repair enzyme NEIL3 drives increased predisposition to autoimmunity. Journal of Clinical Investigation, 2016, 126, 4219-4236.	8.2	56
46	The V Gene Repertoires of Classical and Atypical Memory B Cells in Malaria-Susceptible West African Children. Journal of Immunology, 2015, 194, 929-939.	0.8	36
47	RAG Represents a Widespread Threat to the Lymphocyte Genome. Cell, 2015, 162, 751-765.	28.9	98
48	Circulating Human CD27â^'IgA+ Memory B Cells Recognize Bacteria with Polyreactive Igs. Journal of Immunology, 2015, 195, 1417-1426.	0.8	99
49	TNF receptor superfamily member 13b (TNFRSF13B) hemizygosity reveals transmembrane activator and CAML interactor haploinsufficiency at later stages of B-cell development. Journal of Allergy and Clinical Immunology, 2015, 136, 1315-1325.	2.9	38
50	Salmonella Infection Drives Promiscuous B Cell Activation Followed by Extrafollicular Affinity Maturation. Immunity, 2015, 43, 120-131.	14.3	186
51	Activation-Induced Cytidine Deaminase Expression in Human B Cell Precursors Is Essential for Central B Cell Tolerance. Immunity, 2015, 43, 884-895.	14.3	69
52	Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13447-13454.	7.1	143
53	Lentiviral-mediated gene therapy restores B cell tolerance in Wiskott-Aldrich syndrome patients. Journal of Clinical Investigation, 2015, 125, 3941-3951.	8.2	43
54	Rituximab does not reset defective early B cell tolerance checkpoints. Journal of Clinical Investigation, 2015, 126, 282-287.	8.2	64

#	Article	IF	Citations
55	Dedicator of cytokinesis 8â€“deficient patients have aÂbreakdown in peripheral B-cell tolerance and defectiveÂregulatory T cells. Journal of Allergy and Clinical Immunology, 2014, 134, 1365-1374.	2.9	79
56	Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nature Genetics, 2014, 46, 1135-1139.	21.4	417
57	Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science, 2014, 345, 1623-1627.	12.6	745
58	Signaling lymphocytic activation molecule (SLAM)/SLAM-associated protein pathway regulates human B-cell tolerance. Journal of Allergy and Clinical Immunology, 2014, 133, 1149-1161.	2.9	33
59	Wiskottâ€“Aldrich Syndrome protein deficiency perturbs the homeostasis of B-cell compartment in humans. Journal of Autoimmunity, 2014, 50, 42-50.	6.5	72
60	Potential roles of activation-induced cytidine deaminase in promotion or prevention of autoimmunity in humans. Autoimmunity, 2013, 46, 148-156.	2.6	37
61	Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood, 2013, 121, 1595-1603.	1.4	145
62	Specific peripheral B cell tolerance defects in patients with multiple sclerosis. Journal of Clinical Investigation, 2013, 123, 2737-2741.	8.2	130
63	CVID-associated TACI mutations affect autoreactive B cell selection and activation. Journal of Clinical Investigation, 2013, 123, 4283-4293.	8.2	153
64	IgM+IgD+CD27+ B cells are markedly reduced in IRAK-4â€“, MyD88-, and TIRAP- but not UNC-93Bâ€“deficient patients. Blood, 2012, 120, 4992-5001.	1.4	87
65	Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy. Journal of Clinical Investigation, 2012, 122, 2141-2152.	8.2	55
66	Generation and characterisation of monoclonal antibodies from single RA synovial B cells. Annals of the Rheumatic Diseases, 2012, 71, A40.3-A41.	0.9	0
67	Response: common variable immunodeficiency patients with increased CD21â^'/lo B cells suffer from altered receptor editing and defective central B-cell tolerance. Blood, 2011, 118, 5977-5978.	1.4	12
68	The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases. Annals of the New York Academy of Sciences, 2011, 1246, 1-10.	3.8	128
69	Inflammationâ€independent defective early B cell tolerance checkpoints in rheumatoid arthritis. Arthritis and Rheumatism, 2011, 63, 1237-1245.	6.7	41
70	Activation-induced cytidine deaminase (AID) is required for B-cell tolerance in humans. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11554-11559.	7.1	118
71	The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. Journal of Clinical Investigation, 2011, 121, 3635-3644.	8.2	259
72	Complement receptor 2/CD21â^' human naive B cells contain mostly autoreactive unresponsive clones. Blood, 2010, 115, 5026-5036.	1.4	399

#	Article	IF	Citations
73	The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nature Immunology, 2010, 11, 836-845.	14.5	295
74	B-cell tolerance checkpoints in health and autoimmunity. Current Opinion in Immunology, 2008, 20, 632-638.	5.5	256
75	Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. Journal of Immunological Methods, 2008, 329, 112-124.	1.4	953
76	IRAK-4- and MyD88-Dependent Pathways Are Essential for the Removal of Developing Autoreactive B Cells in Humans. Immunity, 2008, 29, 746-757.	14.3	201
77	Chronic Lymphocytic Leukemia Cells Recognize Conserved Epitopes Associated with Apoptosis and Oxidation. Molecular Medicine, 2008, 14, 665-674.	4.4	174
78	Chronic Lymphocytic Leukemia Cells Recognize Conserved Epitopes Associated with Apoptosis and Catabolic Chemical Modifications. Blood, 2008, 112, 3150-3150.	1.4	1
79	CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance. Journal of Experimental Medicine, 2007, 204, 1583-1593.	8.5	117
80	Autoantibody selection and production in early human life. Journal of Clinical Investigation, 2007, 117, 598-601.	8.2	26
81	B-Cell Chronic Lymphocytic Leukemia (B-CLL) Cells Express Antibodies Reactive with Antigenic Epitopes Expressed on the Surface of Common Bacteria.. Blood, 2006, 108, 25-25.	1.4	13
82	Polyreactive Monoclonal Antibodies Synthesized by Some B-CLL Cells Recognize Specific Antigens on Viable and Apoptotic T Cells.. Blood, 2006, 108, 2813-2813.	1.4	11
83	B-CLL Antibodies Comprised of Stereotypic VH1-69, D3-16, and JH3 Rearrangements Immunoprecipitate Cellular Protein(s).. Blood, 2006, 108, 2816-2816.	1.4	2
84	Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. Journal of Clinical Investigation, 2005, 115, 1636-1643.	8.2	287
85	Impaired early B cell tolerance in patients with rheumatoid arthritis. Journal of Experimental Medicine, 2005, 201, 1659-1667.	8.5	285
86	Defective B cell tolerance checkpoints in systemic lupus erythematosus. Journal of Experimental Medicine, 2005, 201, 703-711.	8.5	612
87	Surrogate Light Chain Expressing Human Peripheral B Cells Produce Self-reactive Antibodies. Journal of Experimental Medicine, 2004, 199, 145-150.	8.5	122
88	Bruton's Tyrosine Kinase Is Essential for Human B Cell Tolerance. Journal of Experimental Medicine, 2004, 200, 927-934.	8.5	131
89	Predominant Autoantibody Production by Early Human B Cell Precursors. Science, 2003, 301, 1374-1377.	12.6	1,806
90	Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. Journal of Clinical Investigation, 2001, 108, 879-886.	8.2	130

#	Article	IF	Citations
91	Autosomal primary immunodeficiencies affecting human bone marrow B-cell differentiation. Immunological Reviews, 2000, 178, 91-98.	6.0	22
92	Circulating human B cells that express surrogate light chains and edited receptors. Nature Immunology, 2000, 1, 207-213.	14.5	109
93	Antibody regulation of B cell development. Nature Immunology, 2000, 1, 379-385.	14.5	229
94	DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature, 2000, 404, 510-514.	27.8	514
95	Immunoglobulin Heavy Chain Variable Region Gene Replacement as a Mechanism for Receptor Revision in Rheumatoid Arthritis Synovial Tissue B Lymphocytes. Journal of Experimental Medicine, 2000, 192, 1151-1164.	8.5	100